Clinical trial
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00014638 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00014638 |
|---|---|
| Title | Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer |
| Official title | Open Label, Multicenter Trial Of Femera (Letrozole) 2.5 mg As First-line Therapy In Postmenopausal Women With Metastatic Breast Cancer Relapsing Following Adjuvant Tamoxifen Therapy |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | letrozole |
| Start date | Jan 1, 2001 |
| Primary completion | Mar 1, 2002 |
| Completion | Mar 1, 2002 |
| First posted | Nov 13, 2003 |
| Last update posted | Feb 21, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: